Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.46 |
| ▸ | PPARG | P37231 | 7/20 | 0.46 |
| ▸ | PPARD | Q03181 | 7/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151120 | 1.00 | CES1 (0.50) | CES1CES2AKR1B1GPR84PPARG | |
| SCHEMBL2946250 | 1.00 | CES1 (0.50) | CES1CES2AKR1B1GPR84PPARG | |
| SCHEMBL14997266 | 0.98 | CES2 (0.52) | CES1CES2GPR84PPARGPPARD | |
| SCHEMBL9308815 | 0.83 | CES2 (0.52) | CES1CES2AKR1B1GPR84PPARG | |
| SCHEMBL9308807 | 0.83 | CES2 (0.52) | CES1CES2AKR1B1GPR84PPARG | |
| Acetic Acid SCHEMBL5172555 | 0.82 | AKR1B1 (0.50) | CES1CES2AKR1B1GPR84PPARG | |
| Acetic Acid SCHEMBL5172556 | 0.82 | AKR1B1 (0.50) | CES1CES2AKR1B1GPR84PPARG | |
| SCHEMBL10600053 | 0.81 | AKR1B1 (0.54) | CES1CES2AKR1B1GPR84PPARG | |
| SCHEMBL2139531 | 0.81 | AKR1B1 (0.54) | CES1CES2AKR1B1GPR84PPARG | |
| SCHEMBL4458027 | 0.80 | CES2 (0.48) | CES1CES2GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100111888-A1 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | claimed |
| EP-2152658-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2010-02-17 | — | — | EP | claimed |
| WO-2008116338-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | claimed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100111888-A1 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-2152658-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2010-02-17 | — | — | EP | disclosed |
| EP-2139354-A2 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116339-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116338-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113460-A1 | Organic Compounds | CYP2B6, CYP2A6, CYP2A13 | CES1 128/4885CES2 52/4885AKR1B1 327/4885 |
| US-20100111888-A1 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions | CYP2A13, CYP1A1, CYP1B1 | CES1 101/4885CES2 95/4885AKR1B1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.